The Only Technology Stock I Am Buying Today
Closely-Guarded Patents Are the Prerequisite for Cutting-Edge Profit Machines
When it comes to biotechnology stocks, timing is everything and this stock is about to transition from the lab phase to real world national expansion and exponential growth.
I have personally sunk my teeth into over 210 companies that own patents and are about to roll out products since October 2016, and nothing even comes close to the combination of well-researched science, aggressive management pressing forward to profitability, a founder that has serious skin in the game, Dr. Sabine Mai, and a series of patents that are secured for 15 years, giving the company a tremendous advantage over any potential competitor.
3D Signatures (TSX-V: DXD & OTC: DTSGF) is the only technology company that has a 10-bagger potential.
When you invest early in cutting-edge futuristic stocks, you better have one predominant thought in mind: Is this company a potential takeover target.
The huge pay-offs are in the exit and with such a tiny company, large pharmaceutical giants are already lining up to sign Non-Disclosure-Agreements and get involved with the new class of biomarkers.
That’s why the founder of this company was named one of Canada’s most powerful women!
She has been able to execute on the highest level.
The Company she founded has over 20 years’ worth of research, more than $25 million spent on R&D, and patents in both North America and Europe for its breakthrough discovery.
The reason that this is such a unique window of opportunity is because these scientists have been so hard at work developing the future of diagnosing and custom-fitting a treatment to cancer and 14 types of diseases, according to the patient’s specific gene build-up that they have been kept under the radar – until now!
The problem that this company tackles is the most fundamental and basic of all: Are you being treated correctly by your doctor?
Doctors have no clue about what is your specific gene code, and misdiagnosis and worst, mistreatment is one the mega-challenges the medical industry is struggling with.
3D Signature’ (TSX-V: DXD & OTC: TDSGF) software optimizes treatment – it is the apex and future of precision medicine, where every patient is checked easily and quickly using their proprietary software to find out exactly what is happening with your body and thus allows the most accurate, detailed and specific information about anyone to be placed in front of the doctor, so he can make the most informed decision – tailored to the patient.
It potentially means once we select a treatment, we can know right away if it’s working, see if there are any adverse side effects, and know if the treatment is doing more harm than good – all in near real-time.
That is why this company is being pursued by giant medical firms!
In 12 months from now, laboratories in Canada and then the U.S. will begin to capitalize on 3D Signatures (TSX-V: DXD & OTC: TDSGF) Patented Technology Software, and it will be game over to investors, as the price of the stock will be super-expensive.
3D Signatures is 1 year away from marketing their product to cancer patients in need of the best and most advanced tools to treat their disease and we can invest in the future by positioning now while the company trades for a ridiculous market value of less than $30 Million Dollars!
Get updates on 3D Signatures and
more Wealth Building Ideas for the new economy.
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought. Wealth Research Group LLC has received one hundred thousand dollars for a ninety day digital marketing agreement. We currently own no shares, but plan to purchase shares seven days after the start of our marketing, all of these shares will have a self-imposed six month hold.
Please read our full disclaimer at WealthResearchGroup.com/disclaimer
Become a Wealth Machine
Be an insider of the breakthrough Science Sector
and stay well ahead of the game!
Get the Exclusive Report on how to profit from Biotechnology now!